Morrison Briggs — SEC Form 4 filings
SEC reporting owner CIK 1654430. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-09 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 50,000 shares, $495,080 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: purchase of 20,000 shares @ $13.40 ($268,070) in ARVINAS, INC., filed 2026-03-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ARVINAS, INC. (ARVN) | Director | 5 | 2 legs · 50,000 sh · $495,080 | — | 6 |
| CRISPR Therapeutics AG (CRSP) | Director | 2 | — | — | 2 |
| Werewolf Therapeutics, Inc. (HOWL) | Director | 2 | — | — | 2 |
| Carisma Therapeutics Inc. (CARM) | Director | 1 | — | — | 1 |
| Repare Therapeutics Inc. (RPTX) | Director | 1 | — | — | 1 |
| Syndax Pharmaceuticals Inc (SNDX) | Director | 1 | — | — | 1 |
Form 4 filings — Morrison Briggs
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | ARVINAS, INC. (ARVN) | Purchase (P): 20,000 @ $13.40 | EDGAR |
| 2025-09-24 | 4 | ARVINAS, INC. (ARVN) | Purchase (P): 30,000 @ $7.57 | EDGAR |
| 2025-06-27 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Werewolf Therapeutics, Inc. (HOWL) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Carisma Therapeutics Inc. (CARM) | Grant/award (A): 19,350 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 5,899 @ $0 · Grant/award (A): 9,070 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Werewolf Therapeutics, Inc. (HOWL) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 17,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1654430 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →